Bioresorbable Scaffolds Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 - 2034
Report ID: GMI3676
Download Free PDF
Authors:
Monali Tayade,
Bioresorbable Scaffolds Market Size
The global bioresorbable scaffolds market generated remarkable revenue in 2024 and is expected to grow at a notable CAGR during 2025-2034 driven by the rising prevalence of cardiovascular diseases, predominantly coronary artery disease (CAD). As per WHO, cardiovascular diseases (CVDs) remained the foremost cause of death worldwide, accounting for approximately 17.9 million fatalities annually. Coronary artery disease continues to be a leading cause of death worldwide, creating an increased need for innovative medical devices aimed at reducing long-term complications.
Bioresorbable scaffolds can provide extra support for the artery as it heals and can be organically degraded - which is a fast-growing appreciation. With a bioresorbable scaffold, one can hypothetically eliminate any risk imposed by leaving a permanent material (i.e. stent) and late stent thrombosis and/or restenosis can be avoided.
The increased adoption of bioresorbable scaffolds is also fueled by advances in materials science that have driven innovation and improvement in the durability and efficacy of devices. As clinical studies continue to emerge, outcomes have indicated bioresorbable scaffolds may potentially deliver superior patient outcomes than a stent, supporting increasing demand from patients and healthcare entities.
Furthermore, the increased prevalence of minimally invasive procedures and the sustained demand for long-term devices that enhance the quality of life for patients are propelling the bioresorbable scaffolds market forward. Drug-eluting scaffolds can aid in addressing long-term concerns for patients and deliver additional benefits such as controlled delivery of anti-proliferative drugs in efforts to improve patient outcomes providing a delay of restenosis acquiescence.
As more healthcare professionals recognize the advantages presented by bioresorbable scaffolds in comparison with traditional metallic stents, there is an increasing shift from the use of metallic stents to bioresorbable scaffolds. Bioresorbable scaffolds have exhibited favorable clinical results insofar as long-term complications like in-stent restenosis and thrombosis have been considerably reduced. Additionally, the advancement of the completely drug-eluting bioresorbable scaffold has been marked as one of the biggest reasons for the growth of the market.
Drug-eluting bioresorbable scaffolds create structural support after deployment and release anti-proliferative drugs to limit the development of in-stent restenosis, which is one of the most frequent complications associated with coronary artery stenting. Thus, scaffold structure support and controlled release of drugs have enhanced demand. The high cost of bioresorbable scaffolds is also expected to limit market growth, specifically, their low mechanical properties including low radial strength when compared to metallic stents. Although the bioresorbable scaffold durability needs to be further developed, the devices must overcome strict steps to gain approval for regulatory review.
Bioresorbable Scaffolds Market Trends
The market is currently undergoing some important trends that will shape its future. One of the most important trends is based on the development of bioresorbable scaffolds with improved material properties to enhance both their degradation rate and mechanical properties. The effort that researchers have undertaken is to improve the materials used in bioresorbable scaffolds such as poly-L-lactic acid (PLLA) and biodegradable magnesium alloys that have better durability and ensure they are completely reabsorbed after use.
This development is significant because the initial failure of bioresorbable scaffolds was because they are mechanically weaker than metallic stents. Another trend is the use of drug-eluting bioresorbable scaffolds. As drug-eluting stents (DES) became a gold standard for coronary interventions, the use of drug-eluting bioresorbable scaffolds is becoming more common. A drug-eluting bioresorbable scaffold is a device that delivers a sustained release of anti-proliferative drugs to discourage local reparative responses to injury and can limit the occurrences of restenosis. The trend of minimally invasive surgery has also affected the growth of bioresorbable scaffolds.
Bioresorbable Scaffolds Market Analysis
The drug-eluting bioresorbable coronary scaffolds segment held a notable share in 2024. DEBCSs can provide structural support, like traditional stents, while also permitting drug release to impede the growth of arterial tissue causing restenosis. Besides their structural support, drug-eluting bioresorbable coronary scaffolds differ from traditional drug-eluting stents (DES), which are made from permanent metal. Bioresorbable scaffolds are intended to dissolve over time after use, reducing a patient's risk for long-term complications and future interventions.
The clinical trial data supporting the numerous advantages of drug-eluting bioresorbable scaffolds (DEBCSs) as compared to metallic scaffolds is increasing annually, driving the need for implantation and subsequent clinical scenarios that help reduce restenosis and improve long-term patient outcomes. Additionally, DEBCS's unique advantage of being suitable for a more extensive patient population could benefit from using DEBCS, including patients with complex coronary anatomy due to favorable material properties. The pace of innovation in terms of materials that offer specific stiffness and faster degradation profiles such as poly-L-lactic acid (PLLA) and magnesium alloys propel market growth.
The hospitals segment from the bioresorbable scaffolds market held the largest share in 2024 as hospitals are the main healthcare providers for patients who suffer from coronary artery disease. In coronary artery procedures, hospitals have offered more advanced cardiac care units to increase the uptake rate of bioresorbable scaffolds. Hospitals with PCI capabilities could be an indicator of bioresorbable scaffold usage as the amount of PCI patients continues to rise.
Hospitals allow for more complex treatment procedures, such as CABG or Angioplasty, or procedures in conjunction with others like bioresorbable scaffolds, to start to implement it in their treatment plans. Hospitals are better facilitated to ensure proper disaster follow-up care is evaluated after bioresorbable scaffold implantation. This is important because continuity of care is a necessity for successful evaluations and ultimately success with the implant once it is bioresorbable scaffolds are implanted.
North America bioresorbable scaffolds market generated notable revenues in 2024. As a result of a high burden of cardiovascular diseases, robust healthcare infrastructure, and a culture of minimally invasive procedures, it contributes to bioresorbable scaffolds trending upward in this region. A rising number of coronary artery disease cases with an increasing older population have the potential to develop the demand for new products bioresorbable scaffolds as an alternative to coronary stents.
Healthcare providers in North America continue to adopt advanced technologies to improve patient outcomes and lessen the likelihood associated with coronary artery disease. Indeed, new product developments clinically and new product approvals are propelling the industry and will only provide additional pathways to new bioresorbable scaffold product approvals. North America fuels market growth, as there are established R&D capabilities at scale to support continuous product development and key players in the business of bioresorbable scaffolds.
Bioresorbable Scaffolds Market Share
Notable players in the bioresorbable scaffolds industry include:
To establish and strengthen the market presence and space, leading companies have implemented a variety of techniques. One typical strategy is continuously developing research and development (R&D) to build on and create new materials and improve scaffold performance. This process improves strength and degradation rates for bioresorbable scaffolds enabling companies to provide scaffolds that could be used safely for longer periods of time, with elite performance in restoring surfaces to their normal function or original anatomy.
Strategic partnerships, collaborations with academic institutions & hospitals, and hands-on experience with markets are important for the development of companies involved in the market space. Partnerships keep companies relevant when they can test the durability of products and offer a platform that assists in testing clinical trials, offering acceptance based on sending samples for regulatory approval to bring new products to the market. In addition, companies are refining their strategic plans by upgrading product portfolios with different countries or emerging regions with developing markets.
Bioresorbable Scaffolds Industry News
In April 2024, Abbott re-entered the field of bio-absorbable, dissolving stents, venturing into relatively new territory. It had secured a groundbreaking approval from the FDA for its newest drug-eluting scaffold, which was developed to treat blocked arteries located below the knee.
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →